|
Horizon Discovery Ltd is a UK biotechnology company based in Cambridge founded in 2007 that provides products and services to support research into personalized medicine.
The company engages in research into human genetic profiles in health and disease as well as the development of targeted therapeutics, with an emphasis on oncology. Using various genome editing technologies, the company modifies the DNA of various cell lines to mimic genetic defects found in the general population which put people at risk of developing specific cancer types, or that predispose them to benefit from a certain cancer treatment. The company supplies products and services hundreds of biotechnology, diagnostic and pharmaceutical companies, and academic research institutes.
In September 2013 Horizon announced 2 major collaborations with Sigma-Aldrich and Harvard University, incorporating the companies' respective nuclease genome-editing technologies into Horizon's GENESIS platform. The first collaboration with Sigma-Aldrich saw the licensing of Zinc Finger Nuclease technology, which provides rapid and efficient knock-out of two or more alleles, complementing the precision of Horizon's proprietary rAAV technology. In the collaboration with Harvard University, Horizon licensed the IP for RNA-guided gene editing system CRISPR, which allows the introduction of a single stranded nick in the genome of mammalian cells, allowing specific specific gene mutations to be created that are not possible with other nuclease technologies.
|
